TRACON Pharmaceuticals, Inc. (TCON)

2,0200 +0,0900 (+4,66 %) À la clôture : 04:00PM EDT

TRACON Pharmaceuticals, Inc.

4350 La Jolla Village Drive
Suite 800
San Diego, CA 92122
United States
858 550 0780
https://www.traconpharma.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 17

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Charles P. Theuer M.D., Ph.D.	Chairman, CEO & President	646,6k	S.O.	1964
Mr. Scott B. Brown CPA, M.S.	Chief Financial Officer	403,1k	S.O.	1981
Dr. James L. Freddo M.D.	Chief Medical Officer	S.O.	S.O.	1955
Mr. Ya Huang	Executive Director of Statistical Programming	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de TRACON Pharmaceuticals, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.